News

Filter

Current filters:

SpirivaAdvair

Generic risk to GSK's Advair prompts buy recommendation from analysts

10-09-2013

Pharmaceutical analysts are urging investors to buy shares of UK pharma major GlaxoSmithKline (LSE: GSK)…

AdvairAstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlinePharmaceuticalRespiratory and PulmonarySandozSpirivaSymbicort

New LABA/LAMA drugs set to fracture COPD market

10-10-2012

The drug market for chronic obstructive pulmonary disease (COPD) therapies will become more fractured…

AdvairBoehringer IngelheimGlaxoSmithKlineGlobalMarkets & MarketingPfizerPharmaceuticalRespiratory and PulmonarySpiriva

Spiriva viewed as most effective drug for COPD by US pulmonologists

21-03-2011

The highest percentage of surveyed US pulmonologists (52%) consider Boehringer Ingelheim/Pfizer’s…

AdvairBoehringer IngelheimGlaxoSmithKlineMarkets & MarketingNorth AmericaPfizerPharmaceuticalRespiratory and PulmonarySpiriva

Increased use of Spiriva will be driven by greater first-line maintenance use

08-12-2010

Privately-held German drug major Boehringer Ingelheim and pharma behemoth Pfizer's (NYSE: PFE) Spiriva…

AdvairBoehringer IngelheimGlaxoSmithKlineMarkets & MarketingPfizerPharmaceuticalRespiratory and PulmonarySpiriva

Back to top